1. Home
  2. OXSQ vs TLSA Comparison

OXSQ vs TLSA Comparison

Compare OXSQ & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Square Capital Corp.

OXSQ

Oxford Square Capital Corp.

HOLD

Current Price

$1.33

Market Cap

151.9M

Sector

Finance

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.21

Market Cap

164.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXSQ
TLSA
Founded
2003
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.9M
164.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
OXSQ
TLSA
Price
$1.33
$1.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.9M
257.0K
Earning Date
04-29-2026
05-04-2026
Dividend Yield
22.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.61
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$1.08
52 Week High
$2.42
$2.60

Technical Indicators

Market Signals
Indicator
OXSQ
TLSA
Relative Strength Index (RSI) 37.65 40.13
Support Level $1.05 N/A
Resistance Level $1.95 $1.54
Average True Range (ATR) 0.10 0.16
MACD 0.01 -0.03
Stochastic Oscillator 75.00 18.83

Price Performance

Historical Comparison
OXSQ
TLSA

About OXSQ Oxford Square Capital Corp.

Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: